Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Compugen Ltd Logo

ARKK Holdings of Compugen (CGEN) - Updated Daily

Date
Direction
Shares
Fund Weight
Fund
August 9, 2022
SELL65.721k0.0009%ARKK
August 8, 2022
SELL46.034k0.0007%ARKK
August 4, 2022
SELL75.871k0.0012%ARKK
August 3, 2022
SELL159.841k0.0027%ARKK
August 2, 2022
SELL35.483k0.0006%ARKK

Key Statistics

DateAugust 04, 2022Revenue
Expected
Actual▫️
EPS
Expected-$0.12
Actual-$0.11
🕵🏼Found In🏷Last Price
ARKKARKGIZRL$1.44
⚖️Weighting🧢Market Cap
0.13%$130.07m
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
3421.68
🏋️‍♀️Weight Rank Across All Funds🌏Country
112🇮🇱Israel
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$9.795.96%
Description
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.
Website
www.cgen.com

Research Notes and Commentary for CGEN